Andrew C Adams
Overview
Explore the profile of Andrew C Adams including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
6044
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li G, Chen H, Shen F, Smithson S, Shealy G, Ping Q, et al.
Hepatology
. 2023 May;
78(5):1506-1524.
PMID: 37129868
Background And Aims: Lipid accumulation induced by alcohol consumption is not only an early pathophysiological response but also a prerequisite for the progression of alcohol-associated liver disease (ALD). Alternative splicing...
2.
Benichou O, Coskun T, Gonciarz M, Garhyan P, Adams A, Du Y, et al.
Cell Metab
. 2023 Jan;
35(2):274-286.e10.
PMID: 36630958
GDF15 and its receptor GFRAL/RET form a non-homeostatic system that regulates food intake and body weight in preclinical species. Here, we describe a GDF15 analog, LY3463251, a potent agonist at...
3.
Samms R, Cheng C, Fourcaudot M, Heikkinen S, Khattab A, Adams J, et al.
Am J Physiol Endocrinol Metab
. 2022 Jun;
323(2):E123-E132.
PMID: 35723225
Fibroblast growth factor 21 (FGF21) is increased acutely by carbohydrate ingestion and is elevated in patients with type 2 diabetes (T2D). However, the physiological significance of increased FGF21 in humans...
4.
Dougan M, Azizad M, Mocherla B, Gottlieb R, Chen P, Hebert C, et al.
Clin Infect Dis
. 2021 Oct;
75(1):e440-e449.
PMID: 34718468
Background: Based on interim analyses and modeling data, lower doses of bamlanivimab and etesevimab together (700/1400 mg) were investigated to determine optimal dose and expand availability of treatment. Methods: This...
5.
Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb R, Chen P, et al.
N Engl J Med
. 2021 Jul;
385(15):1382-1392.
PMID: 34260849
Background: Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive immunity and...
6.
Cohen M, Nirula A, Mulligan M, Novak R, Marovich M, Yen C, et al.
JAMA
. 2021 Jun;
326(1):46-55.
PMID: 34081073
Importance: Preventive interventions are needed to protect residents and staff of skilled nursing and assisted living facilities from COVID-19 during outbreaks in their facilities. Bamlanivimab, a neutralizing monoclonal antibody against...
7.
Taylor P, Adams A, Hufford M, de la Torre I, Winthrop K, Gottlieb R
Nat Rev Immunol
. 2021 Apr;
21(6):382-393.
PMID: 33875867
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical trials. With the US Food and Drug...
8.
Jones B, Brown-Augsburger P, Corbett K, Westendorf K, Davies J, Cujec T, et al.
Sci Transl Med
. 2021 Apr;
13(593).
PMID: 33820835
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics that may...
9.
Ruhlmann C, Dannehl D, Brodtruck M, Adams A, Stenzel J, Lindner T, et al.
J Alzheimers Dis
. 2021 Feb;
80(1):357-369.
PMID: 33554901
Background: To date, there are no effective treatments for Alzheimer's disease (AD). Thus, a significant need for research of therapies remains. Objective: One promising pharmacological target is the hormone fibroblast...
10.
Gottlieb R, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al.
JAMA
. 2021 Jan;
325(7):632-644.
PMID: 33475701
Importance: Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide. Neutralizing antibodies are a potential treatment for COVID-19. Objective: To determine the effect of bamlanivimab monotherapy and combination therapy with...